A Phase I-II Trial Of MK-0646 A Monoclonal Antibody Against Insulin-Like Growth Factor-1 Receptor In Combination With Etoposide And Cisplatin in Extensive Stage Small Cell Lung Cancer.

Trial Profile

A Phase I-II Trial Of MK-0646 A Monoclonal Antibody Against Insulin-Like Growth Factor-1 Receptor In Combination With Etoposide And Cisplatin in Extensive Stage Small Cell Lung Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Dalotuzumab (Primary) ; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Jul 2012 Actual patient number is 12 according to ClinicalTrials.gov.
    • 06 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top